The state of Texas currently has 228 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Tempus Priority Study: A Pan-tumor Observational Study
NCT05179824
Recruiting
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Gender:
All
Ages:
All
Trial Updated:
05/21/2024
Locations: UT Southwestern, Dallas, Texas +1 locations
Conditions: Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer
Register for Updates
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
NCT05667532
Recruiting
To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts
Gender:
Female
Ages:
Between 30 years and 75 years
Trial Updated:
05/21/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
NCT05721248
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT04614194
Recruiting
The purpose of this study is to better understand how the immune system plays a role in fighting breast cancer and specifically research if the immune system response against breast cancer can be improved with endocrine therapy and cyclin dependent kinase inhibitor therapy in patients with hormone receptor positive breast cancer. This will be studied by collecting tumor tissue and blood samples before and after 2 weeks of study treatment with commonly used endocrine therapy and cyclin dependent... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Parkland Hospital, Dallas, Texas +1 locations
Conditions: Breast Cancer
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas +2 locations
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
NCT05596409
Recruiting
The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with ER+/HER2- advanced/metastatic breast cancer who received no prior CDK4/6i in the metastatic setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: UT Health San Antonio Mays Cancer Center, San Antonio, Texas
Conditions: Metastatic Breast Cancer
Register for Updates
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139
Recruiting
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with certain mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors and breast cancer; Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with breast cancer. Each study part will include a 28-day screen... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas +2 locations
Conditions: Breast Cancer, Gynecologic Cancer, HNSCC, Solid Tumors, Adult
Register for Updates
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988
Recruiting
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: M.D. Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Register for Updates
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
NCT03941756
Recruiting
This pilot trial studies whether a procedure called lymphovenous bypass would prevent lymphedema (arm swelling) in patients with inflammatory breast cancer or non-inflammatory breast cancer that has spread to nearby tissues or lymph nodes or melanoma. The lymphovenous bypass procedure creates a path for lymphatic fluid to flow away from the arms. It is usually done after a diagnosis of lymphedema. In this study, giving lymphovenous bypass before underarm lymph node surgery may help prevent lymph... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Melanoma
Register for Updates
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT04042701
Recruiting
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Hope Cancer Center of East Texas, Tyler, Texas
Conditions: Breast Cancer, Non-small Cell Lung Carcinoma
Register for Updates
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
NCT05042687
Recruiting
To evaluate the diagnostic performance of Tc99m sestamibi (MBI) compared to breast MRI in women who are at high risk for developing breast cancer. To assess the relationship of tumor size, histologic subtype and location of lesion and how it affects lesion conspicuity and sensitivity in MBI detected cancers.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
NCT06136884
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas +1 locations
Conditions: Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer
Register for Updates